The basic criteria taken into account when qualifying patients for PCa brachytherapy are the PSA (prostate-specific antigen) concentration, tumor differentiation according to the Gleason classification, and TNM clinical stage [3,4,5]. This evidence concerns the gene KLK3 and posterior cortical atrophy.